组胺H3受体
磷脂病
化学
药理学
亲脂性
体内
反激动剂
广告
赫尔格
兴奋剂
组胺
立体化学
受体
体外
内科学
磷脂
医学
生物化学
生物
生物技术
钾通道
膜
作者
Anil Karbhari Shinde,Rajesh Kumar Badange,Veena Reballi,Pramod Kumar Achanta,Kumar Bojja,Sravanthi Manchineella,Nageswara Rao Muddana,Ramkumar Subramanian,Veera Raghava Chowdary Palacharla,Vijay S. Benade,Pradeep Jayarajan,Jagadeesh Babu Thentu,Bujji Babu Lingavarapu,Sivasekhar Yarra,Narendra Kagita,Mallikarjuna Rao Doguparthi,Abdul Rasheed Mohammed,Ramakrishna V. S. Nirogi
出处
期刊:ChemMedChem
[Wiley]
日期:2021-11-18
卷期号:17 (3): e202100583-e202100583
被引量:4
标识
DOI:10.1002/cmdc.202100583
摘要
A series of chemical optimizations, which was guided by in vitro affinity at histamine H3 receptor (H3R), modulation of lipophilicity, ADME properties and preclinical efficacy resulted in the identification of 1‐[2‐(1‐cyclobutylpiperidin‐4‐yloxy)‐6,7‐dihydro‐4H‐thiazolo[5,4‐c]pyridin‐5‐yl]propan‐1‐one (45 e) as a potent and selective (Ki=4.0 nM) H3R inverse agonist. Dipsogenia induced by (R)‐α‐methylhistamine was dose dependently antagonized by 45 e, confirming its functional antagonism at H3R. It is devoid of hERG and phospholipidosis issues. Compound 45 e has adequate oral exposures and favorable half‐life in both rats and dogs. It has demonstrated high receptor occupancy (ED80=0.22 mg/kg) and robust efficacy in object recognition task and, dose dependently increased acetylcholine levels in brain. The sub‐therapeutic doses of 45 e in combination with donepezil significantly increased acetylcholine levels. The potent affinity, selectivity, in vivo efficacy and drug like properties together with safety, warrant for further development of this molecule for potential treatment of cognitive disorders associated with Alzheimer's disease.
科研通智能强力驱动
Strongly Powered by AbleSci AI